Literature DB >> 26924664

Validation of the 2010 WHO classification and a new prognostic proposal: A single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours.

Claudio Ricci1, Riccardo Casadei2, Giovanni Taffurelli2, Davide Campana2, Valentina Ambrosini3, Nico Pagano2, Donatella Santini3, Roberto De Giorgio2, Carlo Ingaldi2, Paola Tomassetti2, Elia Zani2, Francesco Minni2.   

Abstract

BACKGOUND: In 2010, the World Health Organization (WHO) modified the classification for pancreatic neuroendocrine tumours (NETs). Recently, some modifications were proposed to improve its prognostic value. The aim of this study was to test the prognostic value of both the original and the modified 2010 WHO grading systems.
METHODS: One hundred and twenty consecutive patients surgically resected for well-differentiated NETs were evaluated in multivariate Cox regression models. Age, sex, hormonal status, size, lymph node ratio, stage, margin status and grading were evaluated in order to predict disease-free survival (DFS). Four models were evaluated: model 1: grading according to the 2010 WHO; model 2: modified grading with cut-off at 5% of the Ki-67 index; model 3: modified grading in which the G2 category was divided into two subgroups (2-5% and 5-20%) and model 4: the Ki-67 index as a continuous variable. Decision curve analysis (DCA) was carried out to evaluate the clinical utility of the various cut-offs.
RESULTS: All the grading systems remained independent factors in predicting DFS. Model 2 (c index = 0.814 and P = 0.012) and model 3 (c index = 0.865 and P = 0.015) showed higher predictive powers with respect to model 1 (c index = 0.799). Model 4 had a high predictive value (c index 0.848, P = 0.013). Decision curve analysis confirmed that biological behaviour represented the best prognostic parameter.
CONCLUSION: This study presented some limitations: single centre, retrospective design and a long period of enrolment. The result showed that, by increasing the cut-off of the G2 category to 5% or by creating two subgroups in the G2 category, it was possible to obtain a better stratification of patients.
Copyright © 2016 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Classification; Decision curve analysis; Ki-67; Pancreatic endocrine neoplasm; Surgery; World Health Organization

Mesh:

Substances:

Year:  2016        PMID: 26924664     DOI: 10.1016/j.pan.2016.02.002

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  10 in total

Review 1.  Fit-for-Purpose Immunohistochemical Biomarkers.

Authors:  Emina Emilia Torlakovic
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

2.  Prognostic Assessment of Non-functioning Neuroendocrine Pancreatic Neoplasms as a Basis for Risk-Adapted Resection Strategies.

Authors:  F M Watzka; F Meyer; J I Staubitz; C Fottner; A Schad; H Lang; T J Musholt
Journal:  World J Surg       Date:  2020-02       Impact factor: 3.352

Review 3.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

4.  Short- and long-term outcomes of laparoscopic organ-sparing resection in pancreatic neuroendocrine tumors: a single-center experience.

Authors:  Javier A Cienfuegos; Joseba Salguero; Jorge M Núñez-Córdoba; Miguel Ruiz-Canela; Alberto Benito; Sira Ocaña; Gabriel Zozaya; Pablo Martí-Cruchaga; Fernando Pardo; José Luis Hernández-Lizoáin; Fernando Rotellar
Journal:  Surg Endosc       Date:  2017-01-26       Impact factor: 4.584

5.  Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).

Authors:  Barbara Nuñez-Valdovinos; Alberto Carmona-Bayonas; Paula Jimenez-Fonseca; Jaume Capdevila; Ángel Castaño-Pascual; Marta Benavent; Jose Javier Pi Barrio; Alex Teule; Vicente Alonso; Ana Custodio; Monica Marazuela; Ángel Segura; Adolfo Beguiristain; Marta Llanos; Maria Purificacion Martinez Del Prado; Jose Angel Diaz-Perez; Daniel Castellano; Isabel Sevilla; Carlos Lopez; Teresa Alonso; Rocio Garcia-Carbonero
Journal:  Oncologist       Date:  2018-01-12

6.  The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications.

Authors:  Marcela S Cavalcanti; Mithat Gönen; David S Klimstra
Journal:  Int J Endocr Oncol       Date:  2016-07-14

7.  Neuroendocrine tumors of colon and rectum: validation of clinical and prognostic values of the World Health Organization 2010 grading classifications and European Neuroendocrine Tumor Society staging systems.

Authors:  Chaoyong Shen; Yuan Yin; Huijiao Chen; Sumin Tang; Xiaonan Yin; Zongguang Zhou; Bo Zhang; Zhixin Chen
Journal:  Oncotarget       Date:  2017-03-28

8.  Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.

Authors:  C G Genç; M Falconi; S Partelli; F Muffatti; S van Eeden; C Doglioni; H J Klümpen; C H J van Eijck; E J M Nieveen van Dijkum
Journal:  Ann Surg Oncol       Date:  2018-05-22       Impact factor: 5.344

9.  Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors.

Authors:  G Lamberti; C Ceccarelli; N Brighi; I Maggio; D Santini; C Mosconi; C Ricci; G Biasco; D Campana
Journal:  Gastroenterol Res Pract       Date:  2017-10-29       Impact factor: 2.260

10.  Higher Ki67 expression in fibroblast like cells at invasive front indicates better clinical outcomes in oral squamous cell carcinoma patients.

Authors:  Yue Jing; Yan Yang; Fengyao Hao; Yuxian Song; Xiaoxin Zhang; Ye Zhang; Xiaofeng Huang; Qingang Hu; Yanhong Ni
Journal:  Biosci Rep       Date:  2018-11-20       Impact factor: 3.840

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.